Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Adherium Ltd. ( (AU:ADR) ).
Adherium Limited has applied to the ASX for quotation of 436,729,824 new fully paid ordinary shares, to be issued on 24 February 2026. The large volume of new shares, arising from transactions previously signalled to the market, will expand the company’s listed capital base and may influence liquidity and ownership structure for existing and prospective investors.
The application, lodged as an Appendix 2A, confirms Adherium’s intention to have these securities admitted to trading under its existing issuer code ADR. While the document provides only procedural detail, the scale of the issuance suggests a significant capital or restructuring event that could impact the company’s financial flexibility and market positioning once the shares commence quotation.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australian-listed company in the healthcare technology sector, trading on the ASX under the code ADR. The company focuses on developing and commercialising medical or health-related technologies, though the specific products or services are not detailed in this filing.
Technical Sentiment Signal: Sell
Current Market Cap: A$21.64M
For a thorough assessment of ADR stock, go to TipRanks’ Stock Analysis page.